The Asia-Pacific region is witnessing rapid growth due to the rising prevalence of chronic diseases.
According to MarketSandMarkets Research, the global high content screening (HCS) market is expected to reach $2.19B by 2030, with a CAGR of 7.5%.
The report says that the extended application of artificial intelligence, HCS in personalized medicine, oncology research and cell-based assays contributes to market growth.
In the application, drug discovery and development leads the market, with pharmaceutical and biotech companies being the end users.
The high content imaging platform segment occupied the market in 2024 because of their critical role in cellular analysis, drug discovery and phenotypic screening.
From a regional perspective, the Asia-Pacific region is witnessing rapid growth due to the rising prevalence of chronic diseases, increased investment in health care, and expanded research capabilities.
Countries such as China, India and Japan are making significant progress in biotechnology and drug discovery, which has led to a growing demand for HCS.
